Sclerosant foams

J. C. Wollmann

doi:10.1055/s-0037-1622317

Phlebologie, Inhaltsverzeichnis

Phlebologie 2010; 39(04): 208-217
DOI: 10.1055/s-0037-1622317

Review

Schattauer GmbH

Sclerosant foams

Stabilities, physical properties and rheological behaviorSklerosierungsschaum: Stabilität, physikalische Eigenschaften und rheologisches Verhalten

J. C. Wollmann

¹Kreussler Pharma, Wiesbaden, Germany

› Institutsangaben

Abstract

Summary

Numerous ways of transferring detergent type liquid sclerosants into foam have been described. Out of all techniques, the three most commonly used around the world were selected. Sclerosant foams prepared with different agents and protocols were analyzed in detail, and their rheologic properties were assessed. Some of the results are presented in this review. Results: It is evident that the the material for foam production plays an important role for foam stability, and – connected to this – maybe also for efficacy and safety. Therefore, material that ensures acceptable foam quality should be used exclusively. Out of a huge number of possibilities, the material described in this study was found most suitable. This ensures minimal reduction of foam quality delivered into the vein. Foams considered instable are not clinically ineffective. They have a greater efficacy than the corresponding liquid agent. Foams considered stable seem to need lower injection volumes to have the same or better physical behaviour. Conclusion: Since higher volumes of sclerosant foams are correlated with more side effects, always the smallest effective volumes of foams of appropriate quality are justified.

Zusammenfassung

Zahllose Möglichkeiten sind beschrieben, um aus flüssigen Detergenz-Sklerosierungsmitteln Schäume herzustellen. Die drei am häufigsten verwendeten der zahlreichen Techniken wurden gewählt. Sklerosierungsschäume, die mit unterschiedlichen Sklerosierungsmitteln und nach unterschiedlichen Herstellungsbeschreibungen generiert worden waren, wurden detailliert untersucht und ihre physikalischen Eigenschaften festgestellt. Einige der Ergebnisse werden beschrieben. Ergebnisse: Es ist eindeutig, dass das zur Schaumherstellung verwendete Material die Schaumstabilität erheblich beeinflusst, und – damit zusammenhängend – wohl auch Wirksamkeit und Sicherheit. Daher sollte ausschließlich Material verwendet werden, mit dem sich eine gute Schaumqualität sicher erreichen lässt. Aus einer Reihe ganz unterschiedlicher Möglichkeiten zeigte sich das hier beschriebene als das am Besten geeignete. Es sorgt dafür, dass die Qualität des intravenös gegebenen Schaums nur minimal sinkt. Instabile Schäume sind klinisch nicht ineffektiv, denn sie haben immer eine höhere Wirksamkeit als das zugrunde liegende flüssige Sklerosierungsmittel. Stabile Schäume aber benötigen offenbar geringere Injektionsvolumina um das gleiche oder ein besseres physikalisches Ergebnis zu erzeugen. Schlussfolgerung: Auch weil höhere Schaumvolumina mit mehr unerwünschten Nebenwirkungen korrelieren, sollte stets das geringste noch effektive Volumen eines Schaums ausreichender Qualität verwendet werden.

Keywords

Sclerosant foam stability - Tessari - DSS - polidocanol - sodium tetradecyl sulfate

Schlüsselwörter

Sklerosierungsschaum-Stabilität - Tessari - DSS - Polidocanol - Natriumtetradecylsulfat

Volltext

Referenzen

References
1 Benigni JP, Sadoun S. Télangiectasies et varices réticulaires – Traitement par la mousse d’Aetoxisclérol à 0.25 % – Présentation d’une étude pilote –. Phlébologie 1999; 52: 283-289.
2 Bergan J, Van Le Cheng. Treatment of recurrent varicose veins by sclerosant foam. In: Bergan J, Van Le Cheng. editors. Foam sclerotherapy: A textbook. London: Royal Society of Medicine Press Ltd.; 2008: 193-197.
3 Breu FX, Guggenbichler S, Wollmann JC. 2^nd European Consensus Meeting on Foam Sclerotherapy, April 28–30, 2006, Tegernsee, Germany. VASA 2008; 37 (Suppl. 71) 3-29.
4 Breu FX, Guggenbichler S. European Consensus Meeting on Foam Sclerotherapy. Dermatol Surg 2004; 30: 709-717.
5 BTG plc Press Release: Interim Results. 05 November 2009 www.btgplc.com/view.aspx?ID=204&year=2009
6 BTG plc Press Release: Proposed 2 for 5 rights issue. 12 February 2004 www.btgplc.com/view. aspx?ID=204&year=2004
7 Cavezzi A, Tessari L, Cabrera Garrido AL. Biocompatible gases in foam Sclerotherapy. Aust N Z J Phlebol 2008; 11: 86-87.
8 Cavezzi A, Tessari L, Rosso M, Cabrera Garrido A. Variables in foam sclerotherapy with tessari method: Experimental data. In: XVI World Congress of the Union Internationale de Phlebologie; 2009 Aug 31-Sept 04. Monaco. Int Angiol 2009; 28 (Suppl. 01) 9.
9 Ceulen RPM, Bullens-Goessens YIJM, Pi-Van De Venne SJA. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% Polidocanol foam: Results of a randomized controlled trial with 1-year follow-up. Dermatol Surg 2007; 33: 276-281.
10 Deutsche Gesellschaft für Phlebologie. Guidelines for diagnosis and therapy of venous ulcers (version 8/2008). Phlebologie 2008; 37: 308-329.
11 Durant TM, Stauffer HM, Oppenheimer MJ, Paul RE. Safety of intravascular carbon dioxide and the use for roentgenologic visualization of intracardiac structures. Ann Int Med 1957; 47: 191-201.
12 Eckmann DM, Kobayashi S. Microvascular embolization following Polidocanol microfoam sclerosant administration. Dermatol Surg 2005; 31: 636-643.
13 Epstein PS, Plesset MS. On the stability of gas bubbles in liquid-gas solutions. J Chem Phys 1950; 18: 1505-1509.
14 Flückiger P. Nicht-operative retrograde Varicenverödung mit Varsylschaum. Schweiz Med Wochenschr 1956; 48: 1368-1370.
15 Frullini A. New technique in producing sclerosing foam in a disposable Syringe. Dermatol Surg 2000; 26: 705-706.
16 Gachet G. Une nouvelle mèthode simple et économique pour confectionner de la mousse pour sclérose échoguidée. Phlébologie 2001; 54: 63-65.
17 Gallenkemper G. Foam sclerotherapy: long term foam reproduction of Polidocanol-foam. Two trials with different concentrations under standardized conditions. Phlebologie 2008; 37: 10-15.
18 Gañán-Calvo AM, Fernández JM, Oliver AM, Marquez M. Coarsening of monodisperse wet microfoams. Applied Physics Letters 2004; 84: 4989-4991.
19 Garcia Mingo J. Esclerosis venosa con espuma: „Foam medical system“. Rev Espan Med Cirugia Cosmet 1999; 7: 29-31.
20 Geroulakos G, Davies AH. Crossectomy and foam: Has it got a role in the contemporary management of primary varicose veins?. Phlebology 2009; 24: 1-2.
21 Gonzalez-Zeh R, Armisen R, Barahona S. Endovenous laser and echo-guided foam ablation in great saphenous vein reflux: one year follow-up results. J Vasc Surg 2008; 48: 940-946.
22 Guex JJ, Allaert FA. Immediate and midterm complications of sclerotherapy: Report of a prospective multicenter registry of 12 173 sclerotherapy sessions. Dermatol Surg 2005; 31: 123-128.
23 Guggenbichler S, Breu FX. Survey on the use of foam sclerotherapy in 2005. 6^th European American Congress on Venous Diseases, 26–28 May 2005, Prague, Czech Republic. Praktická Flebologie 2005; 14: 55.
24 Hahn M, Schulz T, Jünger M. Outcome four years after transcatheter foam sclerotherapy of the greater saphenous vein. Phlebologie 2008; 37: 237-240.
25 Hahn M, Schulz T, Jünger M. Sonographically guided, transcatheter foam sclerotherapy of the great saphenous vein. Medical and oeconomic aspects. Phlebologie 2007; 36: 309-312.
26 Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S, Allaert FA. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: Initial results. Dermatol Surg 2003; 29: 1170-1176.
27 Hamel-Desnos C, Ouvry P, Desnos P, Allaert FA. Mousse de Polidocanol à 3% versus 1% dans la sclérothérapie de la grande veine saphéne: Essai controle randomise en double aveugle avec un suivi de 2 ans. Étude 3/1. Phlébologie 2008; 61: 103-109.
28 Kabnick LS, Cayne N, Jacobowitz G, Lamparello P, Maldonado T. et al. Endovenous procedures in varicose veins. What is the best choice today?. Phlebologie 2008; 37: 229-236.
29 Knight RM, Vin F, Zygmunt JA. Ultrasonic guidance of injection into the superficial venous system. Phlébologie ‘89. Davy A, Stemmer R. (eds). John Libbey Eurotext Ltd; 1989: 339-341.
30 Luebke T, Brunkwall J. Systematic review and meta-analysis of endovenous radiofrequency obliteration, endovenous laser therapy, and foam sclerotherapy for primary varicosis. J Cardiovasc Surg (Torino) 2008; 49: 213-233.
31 Mayer H, Brücke H. Angiologie – Zur Ätiologie und Behandlung der Varizen der unteren Extremitäten. Chir Prax 1957; 4: 521-528.
32 Mc Ausland S. The modern treatment of varicose veins. Med Press Circular 1939; 201: 404-410.
33 Monfreux A. Traitement sclérosant des troncs saphéniens et leurs collatérales de gros calibre par la méthode mus. Phlébologie 1997; 50: 351-353.
34 Morrison N, Neuhardt DL, Rogers CR, McEown J, Morrison T, Johnson E, Salles-Cunha SX. Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008; 47: 830-836.
35 Myers KA, Jolley D, Clough A. et al. Outcome of ultrasound-guided sclerotherapy for varicose veins: Medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007; 33: 116-121.
36 Myers KA, Jolley D. Factors affecting the risk of deep venous occlusion after ultrasound-guided sclerotherapy for varicose veins. Eur J Vasc Endovasc Surg 2008; 36: 602-605.
37 Parsi K, Exner T. Technique alterations including leg elevation, immobility, using filters or CO₂ gas do not prevent bubbles from reaching the right heart during foam Sclerotherapy. 11^th Annual Scientific Meeting of Australasian College of Phlebology; 2007 Sep 18–22; Double Bay, Australia. Aust N Z J Phlebol 2008; 11: 85-86.
38 Parsi K. Catheter-directed Sclerotherapy. Phlebology 2009; 24: 98-107.
39 Partsch B. Möglichkeiten der Schaumsklerotherapie. Zeitschrift für Gefäßmedizin 2009; 6: 12-15.
40 Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): A randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg 2008; 35: 238-245.
41 Rabe E, Pannier F, Gerlach H, Breu FX, Guggenbichler S, Wollmann JC. Leitlinien: Sklerosierungsbehandlung der Varikose. Phlebologie 2008; 37: 27-34.
42 Rao J, Goldman MP. Stability of foam in sclerotherapy: difference between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double syringe system (DSS) technique. Dermatol Surg 2005; 31: 19-22.
43 Reich-Schupke S, Altmeyer P, Stücker M. Therapy of insufficiency of the great saphenous vein with catheter-assisted microfoam therapy without heparin. Phlebologie 2008; 37: 198-203.
44 Stücker M, Kobus S, Altmeyer P, Reich-Schupke S. Sclerotherapy with foamed sclerosants. In: Rabe E, Wollmann JC. (eds). Sclero Guide. Bonn: Rabe Medical Publishing; 2009: 65-75.
45 Tessari L. Nouvelle technique d’obtention de la scléro-mousse. Phlébologie 2000; 53: 129.
46 Weaire D, Phelan R. The physics of foam. J Phys: Condens Matter 1996; 8: 9519-9524.
47 Wollmann JC. An experimental model to pinpoint properties and behavior of sclerosing foams. American College of Phlebology 17^th Annual Congress. San Diego, California: August 27–31 2003
48 Wollmann JC. Device for producing a medical foam. European Patent Office, EP1796761A1. 27.09.2005
49 Wollmann JC. Herstellung und Eigenschaften von Sklerosierungsschaum. Vasomed 2004; 16: 24.
50 Wollmann JC. Is there a need to standardize the preparation and the use of sclerosing foam?. Int Angiol 2005; 24: 122.
51 Wollmann JC. Properties and behaviour of sclerosing foams. 6. International Phlebological Symposium. 7–9 November 2003. Bologna, Italy:
52 Wollmann JC. Schaum – zwischen Vergangenheit und Zukunft. Vasomed 2002; 16: 34-35.
53 Wollmann JC. The history of sclerosant foam: persons, techniques, patents and medical improvements. In: Bergan J, Van Le Cheng. (eds). Foam sclerotherapy: A textbook. London: Royal Society of Medicine Press Ltd.; 2008: 3-11.
54 Wollmann JC. The history of sclerosing foams. Dermatol Surg 2004; 30: 694-703.
55 Wright D. Safety and Function of Sclerosant Foams. American College of Phlebology 20^th Annual Congress. November 6–9 2006. Ponte Vedra Beach FL; USA: